In a major industry shift, Hims & Hers will ditch compounded GLP-1s to offer branded Wegovy and Ozempic at self-pay prices following a settlement with Novo Nordisk.
Roche’s Phase III ALLEGORY trial reveals that Gazyva plus standard therapy helped 76.7% of SLE patients achieve significant clinical improvement. New data published in NEJM highlights Gazyva’s potential to redefine the standard of care in lupus by preventing organ damage and reducing steroid dependency.
Roche’s investigational amylin analog, petrelintide, achieved a statistically significant 10.7% mean body weight reduction in a Phase II trial, offering a well-tolerated alternative to current obesity treatments.
Johnson & Johnson announced FDA approval of TECVAYLI plus DARZALEX FASPRO for relapsed/refractory multiple myeloma with unprecedented clinical data demonstrating significant improvements in progression-free survival and overall survival.
Lilly Employer Connect launches with over fifteen administrators to close the U.S. obesity care gap, offering Zepbound® at a discounted price of $449 for employers looking to expand health benefits and reduce employee out-of-pocket costs.
Johnson & Johnson announces FDA Fast Track designation for nipocalimab in systemic lupus erythematosus. The immunoselective therapy demonstrated reduction in lupus disease activity in Phase 2 JASMINE study, offering potential steroid-sparing benefits and accelerated FDA review timeline.
GSK plc announced on March 3, 2026, the completion of its previously announced GSK RAPT Therapeutics acquisition for approximately $2.2 billion, bringing a California-based clinical-stage biopharmaceutical company specializing in novel therapies for inflammatory and immunologic diseases into its portfolio.
In the Phase 3 AFFIRM study, SKYRIZI (risankizumab) achieved superiority in co-primary endpoints of clinical remission and endoscopic response at week 12 for subcutaneous induction in patients with Crohn’s disease.
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has officially closed its acquisition of San Diego-based Avidity Biosciences, marking one of the most significant deals in the neuromuscular disease space in recent years. The transaction, originally announced on October 26, 2025, values Avidity at approximately $12 billion on a fully diluted basis, with an enterprise value of roughly $11 billion.
The FDA has approved PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) as the first perioperative treatment regimen to significantly improve survival in cisplatin-ineligible patients with muscle-invasive bladder cancer. Based on pivotal Phase 3 EV-303 trial data, the combination demonstrated a 60% reduction in recurrence or death risk and a 50% reduction in mortality risk compared to surgery alone.
